Evogene Names Dr. Olga Nissan as New VP of Business Development to Drive Growth

Evogene Welcomes Dr. Olga Nissan as Vice President of Business Development

Evogene Ltd., a leader in computational chemistry known for its innovative generative design of small molecules, has announced the appointment of Dr. Olga Nissan as its new Vice President of Business Development, effective January 1, 2026. Dr. Nissan is recognized for her extensive expertise in the biotechnology and pharmaceutical sectors, making her a valuable addition to the company's leadership team.

Dr. Nissan holds a PhD and has completed postdoctoral research in biochemistry and proteomics at the esteemed Weizmann Institute of Science. Her career spans over 15 years in various key roles, including as Co-Founder and CEO of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX, and Quality Control Domain Manager at Teva Pharmaceutical Industries. Her diverse background equips her with a unique perspective that bridges the gaps between scientific research, business strategy, and funding—critical elements for driving innovation in today's rapidly evolving healthcare environment.

In her new role, Dr. Nissan expressed her enthusiasm about joining Evogene, stating, "I am excited to be part of Evogene at such a pivotal time in the company's expansion. The commitment to translating cutting-edge, AI-driven science into meaningful therapeutic values aligns perfectly with my experience in pharma and biotech." She aims to build strategic partnerships and accelerate the development of innovative discovery programs that can deliver impactful solutions to patients and partners alike.

Evogene's President and CEO, Ofer Haviv, welcomed Dr. Nissan, emphasizing her capacity to enhance the company's drug discovery capabilities. "We believe her expertise in the biotech and AI-driven sectors will play a crucial role as we scale our offerings in small-molecule discovery and optimization powered by our ChemPass AI technology. Her leadership will help us foster collaborations with leading industry partners, translating our real-world innovations into significant value for all stakeholders involved," said Haviv.

Evogene continues to carve its niche in the pharmaceutical and agricultural fields by leveraging its proprietary AI technology, ChemPass AI. This advanced generative AI engine is designed to facilitate the design of highly potent small molecules that are optimized across several critical parameters, fostering improved success rates while curtailing development times and costs.

The company’s strategic approach, termed "Real-World Innovation," integrates scientific advancements with practical industry needs, guiding its mission to create breakthrough products that address real healthcare challenges. Dr. Nissan's appointment underscores Evogene's commitment to bolstering its leadership team with top-tier talent to ensure the successful deployment of its revolutionary solutions.

As Evogene gears up for this next chapter in its growth story, stakeholders can anticipate advancements in both the pharmaceutical and agricultural sectors, driven by the combined expertise of its leadership and a commitment to innovation.

For more information on Evogene and its pioneering technology, visit www.evogene.com.